Catalent (NYSE:CTLT) Stock Rating Lowered by StockNews.com

Catalent (NYSE:CTLT) was downgraded by analysts at StockNews.com from a “hold” rating to a “sell” rating in a report issued on Tuesday.

Other research analysts also recently issued research reports about the stock. Baird R W downgraded shares of Catalent from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, September 24th. Robert W. Baird reaffirmed a “neutral” rating and set a $63.50 price target on shares of Catalent in a research report on Tuesday, September 24th. Finally, William Blair reaffirmed a “market perform” rating on shares of Catalent in a research note on Tuesday, September 3rd. One research analyst has rated the stock with a sell rating and seven have issued a hold rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $63.40.

Catalent Stock Performance

NYSE:CTLT opened at $63.23 on Tuesday. The company has a debt-to-equity ratio of 1.38, a current ratio of 2.51 and a quick ratio of 1.96. The firm has a market cap of $11.48 billion, a PE ratio of -27.98, a P/E/G ratio of 2.46 and a beta of 1.15. The firm has a 50 day simple moving average of $60.20 and a 200-day simple moving average of $58.88. Catalent has a 1-year low of $36.74 and a 1-year high of $63.25.

Catalent (NYSE:CTLT) last issued its quarterly earnings results on Tuesday, November 5th. The company reported ($0.13) earnings per share for the quarter, missing analysts’ consensus estimates of $0.05 by ($0.18). The business had revenue of $1.02 billion for the quarter, compared to analysts’ expectations of $1.06 billion. Catalent had a negative return on equity of 0.66% and a negative net margin of 9.28%. The company’s revenue for the quarter was up 4.2% compared to the same quarter last year. During the same period in the prior year, the company earned ($0.10) EPS. On average, equities analysts expect that Catalent will post 0.84 EPS for the current year.

Insider Transactions at Catalent

In other news, insider David Mcerlane sold 1,994 shares of the company’s stock in a transaction dated Thursday, September 26th. The stock was sold at an average price of $59.97, for a total value of $119,580.18. Following the completion of the sale, the insider now owns 36,304 shares of the company’s stock, valued at $2,177,150.88. This represents a 5.21 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Michelle R. Ryan sold 2,800 shares of the firm’s stock in a transaction dated Monday, November 11th. The shares were sold at an average price of $59.70, for a total value of $167,160.00. Following the sale, the director now owns 10,835 shares in the company, valued at approximately $646,849.50. The trade was a 20.54 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 5,114 shares of company stock valued at $305,931 over the last 90 days. Corporate insiders own 0.31% of the company’s stock.

Institutional Trading of Catalent

Several large investors have recently bought and sold shares of CTLT. Nisa Investment Advisors LLC lifted its stake in shares of Catalent by 1.7% in the second quarter. Nisa Investment Advisors LLC now owns 11,013 shares of the company’s stock worth $619,000 after acquiring an additional 185 shares in the last quarter. Sumitomo Mitsui DS Asset Management Company Ltd increased its holdings in Catalent by 1.1% during the 3rd quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 19,458 shares of the company’s stock worth $1,179,000 after purchasing an additional 220 shares during the last quarter. Crossmark Global Holdings Inc. raised its position in shares of Catalent by 2.6% in the 3rd quarter. Crossmark Global Holdings Inc. now owns 9,133 shares of the company’s stock valued at $553,000 after purchasing an additional 229 shares in the last quarter. Vanguard Personalized Indexing Management LLC raised its position in shares of Catalent by 3.8% in the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 7,688 shares of the company’s stock valued at $432,000 after purchasing an additional 278 shares in the last quarter. Finally, GAMMA Investing LLC grew its position in shares of Catalent by 26.9% during the third quarter. GAMMA Investing LLC now owns 1,310 shares of the company’s stock worth $79,000 after buying an additional 278 shares in the last quarter.

Catalent Company Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.